First Patient Treated Worldwide with the new CyberKnife® M6™ System

USA - Français

USA - Deutsch

European CyberKnife Center to Offer Patients Advanced Radiosurgery Treatments in Munich

News provided by

Feb 04, 2013, 08:30 ET

SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a radiation oncology company, announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) has treated the world's first patient with the new CyberKnife® M6™ System. With the installation of the new system, the Munich center, in close cooperation with the University Hospital of Munich, is the first to offer cancer patients treatment with the CyberKnife M6 System, the latest generation of the CyberKnife System. The new System is now able to provide enhanced quality, a streamlined user interface for treatment delivery and precision to radiation therapy treatments and continues to provide clinical capabilities including non-isocentric, non-coplanar robotic beam delivery and real-time tracking and automatic correction.

"We are pleased to have installed the first CyberKnife M6 System at the European CyberKnife Center Munich-Grosshadern," said Joshua H. Levine, president and chief executive officer of Accuray Incorporated. "The CyberKnife M6 System is the next generation system and will enable clinicians to provide cancer patients with truly personalized treatments."

The ECZM is a global pioneer in radiosurgery. Back in 2005, the center was the first in Germany to have installed a CyberKnife System. As of today, the team of clinicians has treated more than 3,500 patients for intra- and extracranial tumors using CyberKnife SBRT.

"It is vital to offer our patients the best possible care. With the CyberKnife System, we know from experience that extremely accurate outcomes can be achieved. The new system enables us to treat patients significantly faster. Also the treatment will be available to a much bigger patient population. With the CyberKnife Systems we are able to adapt the treatment accurately to the individual needs of each patient's indication," said Prof. Dr. Berndt Wowra, Neurosurgeon and Radiosurgeon.

Dr. Alexander Muacevic, Neurosurgeon, Radiosurgeon and president of the Radiosurgery Society, added: "We will now be able to not only treat small, well-circumscribed tumors, but also larger and irregularly-shaped target structures."

About the European CyberKnife Center, Germany
The European CyberKnife Center Munich (ECZM) was the first center to have a CyberKnife® system installed in Germany. Opened in 2005, it maintains several close scientific and clinical partnerships among which are the University Hospital Charite Berlin and the Stanford University, California/USA. Moreover, the ECZM clinically and scientifically cooperates with the University Clinic of Munich (Ludwig-Maximilians-Universitat, LMU), which contributed significantly to the further development of the technology and the treatment of various indications with CyberKnife®. Until today, the center's team has treated more than 3,500 patients, most of them (71%) for intracranial lesions or tumors. As part of the Radiosurgery Society, the team has accompanied and published many clinical studies (covering topics like e.g. the treatment of spinal tumors, brain metastases or vestibular schwannoma) for which it is perceived as a pioneer of radiosurgery in Germany. For more information please visit www.cyber-knife.net/en.html.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Q filed on November 8, 2012 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated